Vaccine News and Research

Latest Vaccine News and Research

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

Public health nurses with the Sudbury and District Public Health Unit are going to conciliation in their bid to reach a new contract with their employer. Conciliation dates have been set for November 3 and 4, 2009.

20 Oct 2009

AHF reiterates its disappointment over the presentation of Thai HIV vaccine study data

In anticipation of today’s controversial presentation of the Thai HIV vaccine study data at the AIDS Vaccine Conference in Paris, AIDS Healthcare Foundation (AHF) reiterated its disappointment at the news that data that seriously undermined the purported success of the trial were not released publicly when other, more favorable data were reported late last month.

20 Oct 2009

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Phase 3 data reported for the first time show that once every four week subcutaneous injections of SIMPONI(TM) (golimumab) resulted in significantly greater inhibition of structural damage compared with placebo plus methotrexate in patients with active rheumatoid arthritis (RA) and active psoriatic arthritis (PsA).

20 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

ImmunoCellular Therapeutics files a provisional patent application

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, announced today that it has filed a provisional patent application at US Patent Office seeking protection of intellectual property relating to novel glycosylated epitopes present in lung cancer, pancreatic cancer and colon cancer that are targeted by the Company’s ICT-109 monoclonal antibody product candidate.

20 Oct 2009

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

On October 15, 2009, the U.S. Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) issued a joint warning letter to a Web site marketing fraudulent supplements that claim to help prevent the spread of the 2009 H1N1 influenza virus.

20 Oct 2009

Trial collaborators present results from Prime-Boost HIV Vaccine Clinical Trial

Detailed results from the Prime-Boost HIV Vaccine Clinical Trial involving more than 16,000 adult volunteers in Thailand show that an investigational HIV vaccine regimen was safe and modestly effective at reducing the rate of HIV infection compared to placebo.

20 Oct 2009

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

As millions of Americans remain concerned about government-recommended flu shots, dozens of citizens dressed in full haz-mat suits will gather Wednesday, October 21, at the entrance to the Centers For Disease Control (CDC) to greet arriving members of the Advisory Committee on Immunization Practices.

20 Oct 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.

20 Oct 2009

Fluarix seasonal influenza vaccine approved by the FDA

The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.

20 Oct 2009

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that during the A/H1N1 (swine flu) pandemic, GlaxoSmithKline could see its Relenza sales increase if Tamiflu-resistant strains of the virus spread. GlaxoSmithKline recently signed A/H1N1 2009 vaccine contracts with various governments for more than $3 billion and is donating supplies to less wealthy nations, ensuring that the company strikes a balance between profit and public health concerns.

20 Oct 2009

Novel H1N1 influenza raises parents' awareness and concern about seasonal influenza

Novel H1N1 influenza has raised parents' awareness and concern about seasonal influenza, increasing the likelihood that they will get their children vaccinated compared to past years, according to a recent national survey commissioned by the National Foundation for Infectious Diseases (NFID).

20 Oct 2009

Bio-Bridge Science receives business license for Bio-Bridge JRS Biosciences (Beijing)

Bio-Bridge Science, Inc., a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Company received a business license from the Beijing Administration for Industry and Commerce of the People’s Republic of China (“PRC”) indicating approval of the formation of Bio-Bridge JRS Biosciences (Beijing) Co., Ltd. (“Bio-Bridge JRS”).

20 Oct 2009

Opinions: HIV vaccine; HIV resources help promote global disease control; U.S. fight against world hunger

Seth Berkley, president and chief executive of the International AIDS Vaccine Initiative, in a New York Times opinion piece examines how the "pessimism" over the recent controversy surrounding the results of an experimental HIV vaccine tested in Thailand "may ultimately thwart other efforts to develop an AIDS vaccine.

20 Oct 2009

WHO recommends antivirals for patients with symptoms of both H1N1, pneumonia

The WHO concluded a three-day meeting on H1N1 (swine flu) in Washington, D.C., on Friday, where health experts issued recommendations that patients with symptoms of H1N1 and pneumonia be treated quickly with antivirals, even before the results of H1N1 tests are complete, the San Francisco Chronicle blog, "ChronRX" reports (Allday, 10/16).

19 Oct 2009

Experts: Treat swine flu quickly, even without verification

The World Health Organization concluded a three-day meeting on H1N1 (swine flu) in Washington, D.C., on Friday, where health experts issued recommendations that patients with symptoms of H1N1 and pneumonia be treated quickly with antivirals, even before the results of H1N1 tests are complete, the San Francisco Chronicle blog, "ChronRX" reports (Allday, 10/16).

19 Oct 2009

Encorium Group raises $1.6 million through private placement

Encorium Group, Inc., a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced that it has completed a private placement of 3,937,500 shares of its common stock with a private investor for an aggregate purchase price of $1,575,000, or $.40 per share.

19 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Vaccinations and preventative hygiene routines can help protect families from H1N1

According to the Centers for Disease Control and Prevention (CDC), 37 states in the U.S. now report widespread influenza activity - and nearly all influenza cases reported to the health authority are 2009 H1N1, also known as swine flu. However, with the release of a 2009 H1N1 vaccine this week, parents have a new preventative tool to help keep their families safe from illness.

19 Oct 2009

Vaccine News and Research

Latest Vaccine News and Research

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

AHF reiterates its disappointment over the presentation of Thai HIV vaccine study data

SIMPONI treatment results in greater inhibition of structural damage in arthritis patients

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

ImmunoCellular Therapeutics files a provisional patent application

Web site marketing fraudulent H1N1 flu supplements warned by the FDA and the FTC

Trial collaborators present results from Prime-Boost HIV Vaccine Clinical Trial

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

Cangene to acquire U.S. commercialization rights for HepaGam B

Fluarix seasonal influenza vaccine approved by the FDA

GlaxoSmithKline may see increased sales of Relenza during the A/H1N1 2009 pandemic

Novel H1N1 influenza raises parents' awareness and concern about seasonal influenza

Bio-Bridge Science receives business license for Bio-Bridge JRS Biosciences (Beijing)

Opinions: HIV vaccine; HIV resources help promote global disease control; U.S. fight against world hunger

WHO recommends antivirals for patients with symptoms of both H1N1, pneumonia

Experts: Treat swine flu quickly, even without verification

Encorium Group raises $1.6 million through private placement

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Vaccinations and preventative hygiene routines can help protect families from H1N1

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Vaccine News and Research

Latest Vaccine News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in